Department of Anesthesiology, Renmin Hospital of Wuhan University, Wuhan, 430060, Hubei, People's Republic of China.
Department of Anesthesiology, Renmin Hospital of Wuhan University, Wuhan, 430060, Hubei, People's Republic of China.
Biochem Biophys Res Commun. 2018 Sep 10;503(3):1181-1185. doi: 10.1016/j.bbrc.2018.07.022. Epub 2018 Jul 11.
Emerging evidence has supported that TAZ (transcriptional co-activator with PDZ binding motif), one transcription co-activator in Hippo signaling pathway, plays an oncogenic role in liver carcinogenesis. Targeting TAZ could be a potential therapeutic approach for liver cancer patients. In the current study, we aim to determine whether diosgenin could be an inhibitor of TAZ in liver cancer cells. We found that diosgenin inhibited the expression of TAZ in liver cancer cells. Moreover, we found that diosgenin inhibited cell growth, induced apoptosis, suppressed cell migration and invasion in part via inhibition of TAZ in liver cancer cells. Our study provides the evidence to support that diosgenin could be a potential agent for treating human liver cancer.
越来越多的证据表明，TAZ（PDZ 结合基序的转录共激活因子）是 Hippo 信号通路中的一种转录共激活因子，在肝癌发生中发挥致癌作用。靶向 TAZ 可能是肝癌患者的一种潜在治疗方法。在本研究中，我们旨在确定薯蓣皂苷是否可以抑制肝癌细胞中的 TAZ。我们发现薯蓣皂苷可抑制肝癌细胞中 TAZ 的表达。此外，我们发现薯蓣皂苷通过抑制肝癌细胞中的 TAZ，抑制细胞生长，诱导细胞凋亡，抑制细胞迁移和侵袭。我们的研究为薯蓣皂苷可能成为治疗人类肝癌的潜在药物提供了依据。
